Use CE for pre-examination of patients with AUGIB symptoms in emergency centers may reduce the need for emergency electronic gastroscopy and have certain advantages in clinical work. Patients with low-risk lesions can be discharged without the need for EGD and hospitalization, greatly improving the utilization of medical resources.
The investigators plan to conduct exploratory research by sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics, using EGD as the gold standard to evaluate the sensitivity of DS-MCE in diagnosing upper gastrointestinal bleeding lesions and active bleeding.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
120
sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
Changhai hospital
Shanghai, China
The sensitivity of DS-MCE in detection active bleeding and bleeding lesions, using the detection of EGD as the gold standard,
Active bleeding is defined as the continuous flow of visible blood from damaged blood vessels under the microscope. The detection results of bleeding lesions are divided into three categories: P0 refers to lesions without possible bleeding, such as visible submucosal veins, diverticula without bleeding traces, nodules without mucosal damage traces, etc; P1 refers to low-risk bleeding lesions, such as isolated erythema, isolated small erosions, or mucosal damage; P2 refers to high-risk bleeding lesions, such as peptic ulcers (active bleeding or visible blood vessels) with persistent or rebleeding risks, erosions with a diameter of ≥ 2mm, tumors, varicose veins, etc.
Time frame: From enrollment to the end of end of follow-up at 4 weeks
The specificity of ds MCE in detecting active bleeding and bleeding lesions using EGD as the gold standard
Time frame: From enrollment to the end of end of follow-up at 4 weeks
The number of observed signs of bleeding
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Detection rate of bleeding lesions in enrolled subjects
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Detection rate of lesions in enrolled subjects
Time frame: From enrollment to the end of end of follow-up at 4 weeks
The time from the admission of subjects to the detection of bleeding lesions
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Number of therapeutic interventions (endoscopy, DSA, surgery) for enrolled subjects
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From enrollment to the end of end of follow-up at 4 weeks
The time from the admission of subjects to the start of therapeutic interventions (endoscopy, DSA, surgery)
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Detection rate of esophageal, gastric, and small intestinal lesions in enrolled subjects
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Time of traditional electronic gastroscopy examination
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Time of DS-MCE examination
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Incidence of rebleeding in enrolled subjects 30 days after discharge
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Rate of all-cause mortality among enrolled subjects within 30 days of discharge
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Time of hospital stay for enrolled subjects
Time frame: From enrollment to the end of end of follow-up at 4 weeks
Satisfaction of enrolled subjects
use a certain scale named satisfaction scale to measure the satisfaction of enrolled subjects (0-36), lower scores mean a better outcome.
Time frame: From enrollment to the end of end of follow-up at 4 weeks
clinical safety (Incidence of Treatment-Emergent Adverse Events, Safety and Tolerability)
use the incidence of adverse events to measure clinical safety
Time frame: From enrollment to the end of end of follow-up at 4 weeks
complication rate
Time frame: From enrollment to the end of end of follow-up at 4 weeks